Inmazeb ® (atoltivimab, maftivimab, and odesivimab-ebgn) was the first treatment approved by the U.S. Food and Drug Administration (FDA) for Orthoebolavirus zairense, also known as Zaire ebolavirus ...
Regeneron Pharmaceuticals announced that the FDA has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt), a bispecific antibody treatment for adult patients with relapsed or refractory ...
Regeneron Pharmaceuticals is committing $150 million to begin an alliance on a Tessera Therapeutics gene-editing medicine nearing the clinic as a potential treatment for a rare disease that leads to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results